KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,187 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,187 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.87, for a total transaction of $21,585.69. Following the completion of the transaction, the insider now directly owns 97,012 shares of the company’s stock, valued at $957,508.44. The trade was a 2.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $10.09 on Thursday. The company has a market cap of $436.09 million, a P/E ratio of -2.86 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.39 and a 12 month high of $16.88. The company has a 50-day moving average of $10.99 and a 200-day moving average of $11.94.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Wall Street Analysts Forecast Growth

KALV has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new position in KalVista Pharmaceuticals in the second quarter valued at $25,000. China Universal Asset Management Co. Ltd. increased its stake in KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 3,328 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $126,000. SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000. Finally, PEAK6 Investments LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth about $178,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).